Home > Haematological Malignancies > Myeloproliferative Disorders
    Content Type:
  • Myeloproliferative Disorders

    An Introduction to Myeloproliferative Disorders

    Myeloproliferative disorders include a number of conditions that are characterised by excessive accumulation of blood cells or platelets and carry a risk of progression to acute leukaemia. The discovery of mutations in the JAK2, MPL and CALR genes has increased our understanding of the pathogenesis of Philadelphia-negative myeloproliferative neoplasms (PV, MF and ET), leading to improved diagnosis and management. However, JAK2 inhibition has not produced long-term disease remission and there is a need for novel therapeutic targets. Emerging approaches include isocitrate dehydrogenase inhibitors, spliceosome inhibitors, pegylated interferon with ruxolitinib and immune checkpoint inhibitors.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.

    Myeloproliferative Disorders Content

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar